FIELD: medicine.
SUBSTANCE: invention relates to a compound in which n is 2 and A is an antibody containing the heavy and light chain sequences of SEQ ID NO:66 and SEQ ID NO:73, respectively. The invention also provides a compound for which n is 2 or 4 and A is an antibody containing SEQ ID NO:66 and SEQ ID NO:73 or adalimumab.
EFFECT: disclosed is a new compound that is a glucocorticoid receptor agonist and can be used for the treatment of autoimmune and inflammatory diseases.
5 cl, 24 dwg, 22 tbl, 89 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
| NEW CYCLOPENTA[B]BENZOFURANYL DERIVATIVES AND APPLICATION THEREOF | 2005 |
|
RU2415847C9 |
| BINDING AGENT FOR BIOACTIVE PREPARATIONS, METHOD OF ITS SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | 1991 |
|
RU2116087C1 |
| NOVEL COMPOUNDS | 2012 |
|
RU2598840C2 |
| PHENOXYPHENYL ACETIC ACID | 1994 |
|
RU2139273C1 |
| ANELLATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-7-CARBOXAMIDES - INTEGRASE INHIBITORS, METHODS FOR PREPARING AND USING THEREOF | 2019 |
|
RU2717101C1 |
| BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR TREATING NEOPLASTIC AND/OR INFECTIOUS DISEASES | 2016 |
|
RU2730524C2 |
| BICYCLIC TETRAHYDROPYRAZOLEPYRIDINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITION, METHOD OF PHOSPHODIESTERASE INHIBITION, METHOD OF PATIENT TREATMENT | 1994 |
|
RU2131876C1 |
| PRODUCTION OF COMPOUNDS AND COMPOSITIONS FOR SUPPRESSION OF SHP2 ACTIVITY | 2019 |
|
RU2797951C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
